Cost of capital is beyond our reach
Article Abstract:
Cost of capital is no doubt significant in principle as a criterion for checking out the value of equity, bonds, corporate plans and acquisition targets, but its most reflected weakness is that it cannot be defined or measured within meaningful bounds. Management should hence end their doomed, misleading and expensive quest for cost of capital computations until new insights become available.
Publication Name: Accountancy
Subject: Business
ISSN: 0001-4664
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
An instrumental standard
Article Abstract:
The International Accounting Standards Board (IASB) believes that users of financial statements would benefit from information about an entity's exposure to risk and how those risks are managed. The IASB has hence issued an Exposure Draft, ED 7, Financial Instruments: Disclosures, containing proposals to improve disclosures about financial instruments in financial statements.
Publication Name: Accountancy
Subject: Business
ISSN: 0001-4664
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
The covenant question
Article Abstract:
An argument is presented that covenants that apparently ensure safer private equity deals are actually unnecessary restrictions whose protectiveness undermines the very safeguards they are supposed to provide.
Publication Name: Accountancy
Subject: Business
ISSN: 0001-4664
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Collision course. Tweaking the standards
- Abstracts: Keeping the high ground. An unusual ambition. Easy when you know how
- Abstracts: Duration estimates and users' preferences in human-computer interaction. Performance with tables and graphs: effects of training and a Visual Search Model
- Abstracts: Beyond competition: institutional isomorphism in U.S. accounting research. Is accounting an academic discipline?
- Abstracts: Positive clinical data in Parkinson's and ischemia buoy gene therapy. Commercial interest grows in glycan analysis